other

CytoSelect 24-well Cell Migration and Invasion Assay (8 um), Colorimetric, Combo Kit

MBS168726

2 x12 Assays

935 USD

Assay Kit

CytoSelect 24-well Cell Migration and Invasion Assay (8 um), Colorimetric, Combo Kit

[CytoSelect Cell Migration and Invasion Assay (8 um)]

[CytoSelect 24-well Cell Migration and Invasion Assay (8 um), Colorimetric, Combo Kit]

Store all components at 4 degree C until their expiration dates.

Testing Data

Testing Data #2

Testing Data #3

Testing Data #4

Cell Based Assays; Cell Migration; Invasion and Wound Healing; Boyden Chamber Assays; Chemotaxis / Cell Invasion Combo Kits

Background: Cell migration is a highly integrated, multistep process that orchestrates embryonic morphogenesis, tissue repair and regeneration. It plays a pivotal role in the disease progression of cancer, mental retardation, atherosclerosis, and arthritis. The initial response of a cell to a migration-promoting agent is to polarize and extend protrusions in the direction of the attractant; these protrusions can consist of large, broad lamellipodia or spike-like filopodia. In either case, these protrusions are driven by actin polymerization and can be stabilized by extracellular matrix (ECM) adhesion or cell-cell interactions (via transmembrane receptors). The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the significant morbidity and mortality of cancers. Invasiveness requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Metastatic cells produce many proteolytic enzymes (e.g. lysosomal hydrolysates, collagenases, plasminogen activators) while the expression of certain cell surface protease receptors is also increased. CytoSelect™ Cell Migration Assay utilizes polycarbonate membrane inserts (8 um pore size) to assay the migratory properties of cells. The 8 um pore size is optimal for epithelial and fibroblast cell migration. However, in the case of leukocyte chemotaxis, a smaller pore size (3 um) is recommended. CytoSelect™ Cell Invasion Assay utilizes basement membrane-coated inserts to assay the invasive properties of tumor cells. Each assay contains sufficient reagents for the evaluation of 12 samples.

1. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR. (2003) Science 302, 1704-9. 2. Horwitz R, Webb D. (2003) Curr Biol. 13, R756-9. 3. Lauffenburger DA, Horwitz AF. (1996) Cell 84, 359-369. 4. Erkell, L. J., Schirrmacher, V. (1988) Cancer Res 48, 6933-6937. 5. Montgomery, A. M. P., De Clerck, Y. A., Langley, K. E., Reisfeld, R. A., Mueller, B. M. (1993) Cancer Res 53,693-700. 6. Monsky, W. L., Lin, C. Y., Aoyama, A., Kelly, T., Akiyama, S. K., Mueller, S. C., Chen, W. T. (1994) Cancer Res 54,5702-5710. 1. Cai, X. Z. et al. (2015). iTRAQ-based quantitative proteomic analysis of nasopharyngeal carcinoma. J Cell Biochem. doi: 10.1002/jcb.25105. 2. Zheng, X. et al. (2015). Targeting LunX inhibits non-small-cell lung cancer growth and metastasis. Cancer Res. doi: 10.1158/0008-5472. 3. Kim, K. S. et al. (2015). Increased expression of endocan in arthritic synovial tissues: Effects of adiponectin on the expression of endocan in fibroblast-like synoviocytes. Mol Med Rep. 11:2695-2702. 4. Li, M. et al. (2013). Physiological role of the interaction between CARMIL1 and capping protein. Hum. Reprod. 28:2822-2831. 5. Majid, S. et al. (2013). miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer. Res. 19: 73-84. 6. Majid, S. et al. (2012). miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 72:6435-6446. 7. Shin, S.Y. et al. (2012). Transcriptional regulation of the Interleukin-11 gene by oncogenic Ras. Carcinogenesis 10.1093/carcin/bgs297. 8. Saini, S. et al. (2012). miRNA-708 control of CD44+ prostate cancer-initiating cells. Cancer. Res. 72: 3618-3630. 9. Dennis, M. et al. (2012). Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells. Otolaryngology--Head and Neck Surgery. 147: 726-732. 10. Dalezis, P. et al. (2012). Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model. In Vivo 26:75-86. 11. Kahlert, C. et al. (2011). Overexpression of ZEB2 at the invasion front of colorectal cancer is an Iindependent prognastic marker and regulates tumor invasion in vitro. Clin. Cancer Res. 17:7654-7663. 12. Shin, S.Y. et al. (2010). TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J. Biol. Chem. 285: 30731-30740. 13. Eckstein, N. et al. (2008). EGFR-pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J. Biol. Chem. 283: 739-750. 14. Liu, S. et al. (2008). Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J. Biol. Chem. 283: 529-540. 15. Ke, X-S. et al. (2008). Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One 3(10):e3368. 16. Isakova, I. et al. (2007). Age and dose-related effects on MSC engraftment levels and anatomical distribution in the CNS of non-human primates: identification of novel MSC subpopulations that respond to guidance cues in brain. Stem Cells 25: 3261-3270.17. Phinney, D. et al. (2006). Murine mesenchymal stem cells transplanted to the central nervous system of neonatal versus adult mice exhibit distinct engraftment kinetics and express receptors that guide neuronal cell migration. Stem Cells Dev. 15(3): 437-447.

2 x12 Assays

935 USD

10x12 Assays

3760